Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658273 | 0.71 | LMNA (0.38) | GRM5LMNA | |
| SCHEMBL19766422 | 0.71 | LMNA (0.38) | GRM5LMNA | |
| SCHEMBL8536551 | 0.69 | ALDH1A1 (0.35) | GRM5LMNACHRNA7 | |
| SCHEMBL2014082 | 0.67 | ALDH1A1 (0.36) | LMNA | |
| SCHEMBL15471013 | 0.64 | PIK3CD (0.31) | — | |
| SCHEMBL12211798 | 0.61 | L3MBTL1 (0.76) | L3MBTL1GAALMNA | |
| SCHEMBL20198794 | 0.61 | L3MBTL1 (0.76) | L3MBTL1GAALMNA | |
| SCHEMBL13993378 | 0.61 | L3MBTL1 (0.34) | L3MBTL1GAA | |
| SCHEMBL12659705 | 0.61 | L3MBTL1 (0.34) | L3MBTL1GAA | |
| SCHEMBL13993382 | 0.61 | HSD11B1 (0.40) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059799-B2 | Process for preparation of eribulin and intermediates thereof | DR. REDDY'S LABORATORIES LIMITED. (IN) | 2021-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059799-B2 | Process for preparation of eribulin and intermediates thereof | ERLIN1, ERLIN2, MAN1B1 | L3MBTL1 4553/4885GRM5 2774/4885GAA 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.